116 related articles for article (PubMed ID: 19846251)
1. What is the optimal treatment strategy for T1 bladder tumors?
Babjuk M
Eur Urol; 2010 Jan; 57(1):32-4. PubMed ID: 19846251
[No Abstract] [Full Text] [Related]
2. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
[TBL] [Abstract][Full Text] [Related]
3. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
4. The management of superficial bladder cancer.
Dalbagni G
Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment on: Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
Gofrit ON
Eur Urol; 2009 Nov; 56(5):836. PubMed ID: 18926619
[No Abstract] [Full Text] [Related]
6. T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. Pro.
Clark PE
Oncology (Williston Park); 2013 Sep; 27(9):872, 921. PubMed ID: 24282982
[No Abstract] [Full Text] [Related]
7. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.
Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A
Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595
[TBL] [Abstract][Full Text] [Related]
8. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.
DiBianco JM; George AK; Su D; Agarwal PK
Curr Opin Urol; 2015 Sep; 25(5):468-75. PubMed ID: 26125507
[TBL] [Abstract][Full Text] [Related]
9. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM;
Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824
[TBL] [Abstract][Full Text] [Related]
10. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
11. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
[TBL] [Abstract][Full Text] [Related]
12. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
Bercovich E; Deriu M; Manferrari F; Irianni G
Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer: current optimal intravesical treatment.
Lamm DL; McGee WR; Hale K
Urol Nurs; 2005 Oct; 25(5):323-6, 331-2. PubMed ID: 16294610
[TBL] [Abstract][Full Text] [Related]
14. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
15. Current problems and needs in the treatment of pT1 G3 bladder carcinoma.
Martínez Portillo FJ; Alken P
Int Urol Nephrol; 2002; 33(1):29-40. PubMed ID: 12090335
[No Abstract] [Full Text] [Related]
16. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease.
van Rhijn BW; Burger M
Nat Rev Urol; 2016 Oct; 13(10):570-1. PubMed ID: 27578042
[No Abstract] [Full Text] [Related]
18. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
20. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
